Dixestivo
Servizo
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublicacións en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (2)
2023
-
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
The Lancet Oncology, Vol. 24, Núm. 12, pp. 1399-1410
2009
-
A C-terminal mutation of ATP1A3 underscores the crucial role of sodium affinity in the pathophysiology of rapid-onset dystonia-parkinsonism
Human Molecular Genetics, Vol. 18, Núm. 13, pp. 2370-2377